Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)
Thorsten Braun, Claude Gardin
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 7, pp. 803-811
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H. Pillow, Pragya Adhikari, Robert A. Blake, et al.
ChemMedChem (2019) Vol. 15, Iss. 1, pp. 17-25
Closed Access | Times Cited: 153
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Sarina A. Piha‐Paul, Jasgit C. Sachdev, Minal Barve, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 21, pp. 6309-6319
Open Access | Times Cited: 137
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortés, et al.
Haematologica (2020) Vol. 106, Iss. 3, pp. 894-898
Open Access | Times Cited: 119
A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, et al.
Cancer (2021) Vol. 127, Iss. 16, pp. 2943-2953
Open Access | Times Cited: 58
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus, Tianyu Cai, Courtney D. DiNardo, et al.
Blood Cancer Journal (2019) Vol. 9, Iss. 2
Open Access | Times Cited: 65
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Juncheng Chen, Pan Tang, Yuxi Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5184-5211
Closed Access | Times Cited: 36
The role of protein acetylation in carcinogenesis and targeted drug discovery
Jingru Yang, Cong Song, Xianquan Zhan
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 29
Recent advances in the understanding and treatment of acute myeloid leukemia
Justin M. Watts, Stephen D. Nimer
F1000Research (2018) Vol. 7, pp. 1196-1196
Open Access | Times Cited: 59
Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins
Deheng Chen, Tian Lu, Ziqin Yan, et al.
European Journal of Medicinal Chemistry (2019) Vol. 182, pp. 111633-111633
Closed Access | Times Cited: 51
Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia
Kyle A. Romine, Tamilla Nechiporuk, Daniel Bottomly, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 5, pp. 518-531
Open Access | Times Cited: 30
Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
Cunte Chen, Ling Xu, Rili Gao, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 29
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo
Ulrike Tontsch-Grunt, Dorothea Rudolph, Irene C. Waizenegger, et al.
Cancer Letters (2018) Vol. 421, pp. 112-120
Open Access | Times Cited: 33
Design, Synthesis, and Evaluation of Thienodiazepine Derivatives as Positron Emission Tomography Imaging Probes for Bromodomain and Extra-Terminal Domain Family Proteins
Ping Bai, Yu Lan, Debasis Patnaik, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 19, pp. 14745-14756
Closed Access | Times Cited: 25
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Krzysztof Brzezinka, Ekaterina Nevedomskaya, Ralf Lesche, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Non-oncogene dependencies: Novel opportunities for cancer therapy
Tiziana Di Marco, Mara Mazzoni, Angela Greco, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116254-116254
Closed Access | Times Cited: 3
Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE
Andrew D.J. Pearson, Steven G. DuBois, Victoria Buenger, et al.
European Journal of Cancer (2021) Vol. 146, pp. 115-124
Open Access | Times Cited: 19
Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells
Shreeya Bakshi, Christina McKee, Keegan Walker, et al.
Oncotarget (2018) Vol. 9, Iss. 73, pp. 33853-33864
Open Access | Times Cited: 22
Predicting response to BET inhibitors using computational modeling: A BEAT AML project study
Leylah Drusbosky, Robinson Vidva, Saji Gera, et al.
Leukemia Research (2019) Vol. 77, pp. 42-50
Open Access | Times Cited: 20
BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia
Haley E. Ramsey, Dalton Greenwood, Susu Zhang, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 2, pp. 598-607
Open Access | Times Cited: 20
New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm
Xiang Zhang, Jiewen Sun, Min Yang, et al.
Critical Reviews in Oncology/Hematology (2020) Vol. 149, pp. 102928-102928
Closed Access | Times Cited: 19
Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Leticia Serrano‐Oviedo, Miriam Nuncia‐Cantarero, Sara Morcillo-García, et al.
Cellular Oncology (2020) Vol. 43, Iss. 3, pp. 431-444
Open Access | Times Cited: 17
4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines
Martin Hügle, Pierre Regenass, Robin Warstat, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 24, pp. 15603-15620
Closed Access | Times Cited: 16
Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies
Zoe McKinnell, Daniel Karel, Daniel Tuerff, et al.
Journal of Hematology (2022) Vol. 11, Iss. 6, pp. 197-209
Open Access | Times Cited: 10
Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease
Katiri Snyder, Hannah Choe, Yandi Gao, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 12
Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
Hanane Djamai, Jeannig Berrou, Mélanie Dupont, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1704-1704
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top